報價延遲最少15分鐘:2026/02/28 13:45 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
8.38 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.14/-1.24
|
|
企業價值
582.36M
|
| 資產負債 |
|
每股賬面淨值
3.01
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
80.00M
|
|
每股收益
0.04
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF inductionand improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases. |
